Antibacterials: Are the new entries enough to deal with the emerging resistance problems?

Current Opinion in Biotechnology

Volumn 14, Issue 6, 2003, Pages 621-626

  Barrett, Christine T ^a   Barrett, John F ^b  

^a PRINCETON UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 AMINO 3,5 DIFLUORO 2 PYRIDYL) 8 CHLORO 6 FLUORO 1,4 DIHYDRO 7 (3 HYDROXY 1 AZETIDINYL) 4 OXO 3 QUINOLINECARBOXYLIC ACID; 7 [[(2 AMINO 5 CHLORO 4 THIAZOLYL)(HYDROXYIMINO)ACETYL]AMINO] 3 [[3 [[(2 AMINOETHYL)THIO]METHYL] 4 PYRIDINYL]THIO] 8 OXO 5 THIA 1 AZABICYCLO[4.2.0]OCT 2 ENE 2 CARBOXYLIC ACID; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN; DALBAVANCIN; DAPTOMYCIN; GARENOXACIN; GLYCOPEPTIDE; HYDROXAMIC ACID; LIPOPEPTIDE; MACROLIDE; N [1 TERT BUTYL 2 OXO 2 [4 (2 THIAZOLYLMETHYL) 1 PIPERAZINYL]ETHYL] 3 CYCLOPENTYL 2 (N FORMYL N HYDROXYAMINOMETHYL)PROPIONAMIDE; ORITAVANCIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; PHENYLALANYLARGININE 2 NAPHTHYLAMIDE; PNU 288034; QUINOLONE; RAMOPLANIN; STREPTOMYCIN DERIVATIVE; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; VRC 4887;

ANTIBIOTIC RESISTANCE; BACTERIAL GENOME; BACTERIAL GROWTH; BIODIVERSITY; BIOTECHNOLOGY; DRUG SYNTHESIS; ECOLOGICAL NICHE; GENE SEQUENCE; MEDICAL RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

BACTERIA (MICROORGANISMS); THIA;

EID: 0345549544     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2003.10.003     Document Type: Review

References (56)

1. Abbanat D., Macielag M., Bush K. Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert Opin. Investig. Drugs. 12:2003;379-399.
2. Phillips O.A. Antibacterial agents: patent highlights July to December 2002. Curr. Opin. Investig. Drugs. 4:2003;117-127.
3. Bronson J., Barrett J.F. Quinolones, Everninomycins, Glycylglycines, Carbapenems, Lipopeptides, and Cephem antibacterials in clinical development. Curr. Med. Chem. 8:2001;1775-1793.
4. Chopra I., Hesse L., O'Neill A.J. Exploiting current understanding of antibiotic action for the discovery of new drugs. J. Appl. Microbiol. 92:2002;4S-15S.
5. Douthwaite S. Structure-activity relationships of ketolides versus macrolides. Clin. Microbiol. Infect. 7(Suppl. 3):2001;11-17.
6. Smith J.T., Lewin C.S. Mechanisms of antimicrobial resistance and implications for epidemiology. Vet. Microbiol. 35:1993;233-242.
7. Lakaye B., Dubus A., Lepage S., Groslambert S., Frere J.M. When drug inactivation renders the target irrelevant to antibiotic resistance: a case story with β-lactams. Mol. Microbiol. 31:1999;89-101.
8. Haddad J., Kotra L.P., Llano-Sotelo B., Kim C., Azucena E.F. Jr., Liu M., Vakulenko S.B., Chow C.S., Mobashery S. Design of novel antibiotics that bind to the ribosomal acyltransfer site. J. Am. Chem. Soc. 124:2002;3229-3237.
9. Bonfiglio G., Russo G., Nicoletti G. Recent developments in carbapenems. Expert Opin. Investig. Drugs. 11:2002;529-544.
10. Therrien C., Levesque R.C. Molecular basis of antibiotic resistance and β-lactamase inhibition by mechanism-based inactivators: perspectives and future directions. FEMS Microbiol. Rev. 24:2000;251-262.
11. Xiong Y.Q., Yeaman M.R., Bayer A.S. Linezolid: a new antibiotic. Drugs Today (Barc.). 36:2000;631-639.
12. Johnson A.P. The future prospects of oxazolidinones. IDrugs. 6:2003;240-245.
13. Forsyth R.A., Haselbeck R.J., Ohlsen K.L., Yamamoto R.T., Xu H., Trawick J.D., Wall D., Wang L., Brown-Driver V., Froelich J.M.et al. A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol. Microbiol. 43:2002;1387-1400 An excellent overview of the 'genomics' process in an applied environment.
14. Ji Y. The role of genomics in the discovery of novel targets for antibiotic therapy. Pharmacogenomics. 3:2002;315-323.
15. Barker K.F. Antibiotic resistance: a current perspective. Br. J. Clin. Pharmacol. 48:1999;109-124.
16. McDevitt D., Payne D.J., Holmes D.J., Rosenberg M. Novel targets for the future development of antibacterial agents. J. Appl. Microbiol. 92:2002;28S-34S.
17. Waterman S.R. Bacterial genomics as a potential tool for discovering new antimicrobial agents. Am. J. Pharmacogenomics. 1:2001;263-269.
18. Anonymous: IMS Reports, 2000. IMS Health Incorporated, Fairfield, CT, USA. URL: http://secure.imshealth.com.
19. Anonymous. Pharma 500, Annual Report: Top 500 Drugs: Pharma Business, May 2000, p 58. Engel Publishing/Pharma Business, West Trenton, NJ, USA.
20. Adam D. Global antibiotic resistance in Streptococcus pneumoniae. J. Antimicrob. Chemother. 50(Suppl.):2002;1-5.
21. Turner P.J., Greenhalgh J.M. The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000. Clin. Microbiol. Infect. 9:2003;563-567.
22. Vanhoof R., Carpentier M., Cartuyvels R., Damee S., Fagnart O. Surveillance of antibiotic resistance in clinical isolates of Streptococcus pneumoniae. Acta Clin. Belg. 58:2003;111-119.
23. Sarah-Ginsburg A., Grosset J.H., Bishai W.R. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis. 3:2003;432-442.
24. Wazait H.D., Patel H.R., Veer V., Kelsey M., Van Der Meulen J.H. Catheter-associated urinary tract infections: prevalence of uropathogens and pattern of antimicrobial resistance in a UK hospital (1996-2001). BJU Int. 91:2003;806-809.
25. Ug A., Ceylan O. Occurrence of resistance to antibiotics, metals, and plasmids in clinical strains of Staphylococcus spp. Arch Med. Res. 34:2003;130-136.
26. Barlow M., Hall B.G. Experimental prediction of the natural evolution of antibiotic resistance. Genetics. 163:2003;1237-1241 A thorough experimental paper on the power of selection which models the evolution of bacterial susceptibility in nature.
27. Barrett J.F. Antimicrobial resistance - should we be concerned? Expert Opin. Pharmacother. 2:2001;201-204.
28. Farrell D.J., Morrissey I., Bakker S., Felmingham D. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J. Antimicrob. Chemother. 50(Suppl. 1):2002;39-47.
29. Chopra I., O'Neill A.J., Miller K. The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist Updat. 6:2003;137-145.
30. Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J. Antimicrob. Chemother. 51:2003;1109-1117.
31. Therrien C., Levesque R.C. Molecular basis of antibiotic resistance and β-lactamase inhibition by mechanism-based inactivators: perspectives and future directions. FEMS Microbiol. Rev. 24:2000;251-262.
32. Mathai D., Lewis M.T., Kugler K.C., Pfaller M.A., Jones R.N. Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I - results from the SENTRY antimicrobial surveillance program. Diagn. Microbiol. Infect Dis. 39:2001;105-116.
33. Ichiyama S., Mori T., Yamaguchi K., Yamanaka K., Kurokawa Y., Uehara N., Takahashi C., Negayama K., Kaneko Y., Hirakata Y. Nationwide sensitivity surveillance of various antibiotic activities against bacteria isolated from patients with severe infections. Jpn. J. Antibiot. 54:2001;401-447.
34. Ehrhardt A.F., Russo R. Clinical resistance encountered in the respiratory surveillance program (RESP) study: a review of the implications for the treatment of community-acquired respiratory tract infections. Am. J. Med. 111(Suppl. 9A):2001;30S-38S.
35. Jones R.N., Pfaller M.A. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patters of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program. Clin. Infect Dis. 31(Suppl. 2):2000;S16-S23.
36. Andrade S.S., Jones R.N., Gales A.C., Sader H.S. Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY antimicrobial surveillance program (1997-2001). J. Antimicrob. Chemother. 52:2003;140-141.
37. Tunidge J., McCarthy L.R., Master R.N., Kepner D.E. Low levels of fluoroquinolone resistance in Escherichia coli. A five year trend in Australia measured through the use of TSN database Australia. Commun. Dis. Intel. 27(Suppl.):2003;S89-S91.
38. Cohen M.L. Changing patterns of infectious diseases. Nature. 406:2000;762-767 An excellent overview of the changing landscape of existing and emerging problems in infectious disease control.
39. Avorn JL, Barrett JF, Davey PG, McEwen SA, O'Brien TF, Levy SB: Antibiotic resistance: synthesis of recommendations by Expert Policy Groups (1987-2000). 2001. Commissioned by the World Health Organization. URL: http://www.who.int/emc/amrpdfs/ Antimicrobial_resistance_recommendations_of_expert_polic.pdf.
40. Urban C., Segal M., Radal J.J. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin. Infect Dis. 36:2003;1268-1274.
41. Finch R. Bacterial resistance - the clinical challenge. Clin. Microbiol. Infect. 8(Suppl. 3):2002;21-32 An outstanding review on the practical aspects of resistance and it's toll on clinical outcomes. Provides excellent linkage between esoteric in vitro resistance and real life in the medical community.
42. Felmingham D. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance program. Prospective resistant organism tracking and epidemiology for the ketolide telithromycin. J. Infect. 44(Suppl. A):2002;3-10.
43. Sefton A.M. Mechanisms of antimicrobial resistance: their clinical relevance in the new millennium. Drugs. 62:2002;557-566 An excellent summary of all relevant resistances in both the hospital and community. A clear understanding of the clinical cost is also provided.
44. Morbidity and Mortality World Reports: 2002, pp. xx-xxiv. URL: http://www.cdc.gov/mmwr/PDF/wk/mm5053.pdf.
45. Silver L., Bostian K. Screening of natural products for antimicrobial agents. Eur. J. Clin. Microbiol. Infect Dis. 9:1990;455-461.
46. Dougherty T.J., Pucci M.J., Barrett J.F. Antimicrobial resistance - why do we have it and what can we do about it? Expert Opin. Investig. Drugs. 9:2000;1707-1709.
47. Guerrant R.L., Blackwood B.L. Threats to a global survival: the growing crisis of infectious diseases - our 'unfinished agenda'. Clin. Infect Dis. 28:1999;966-986.
48. Monroe S., Polk R. Antimicrobial use and bacterial resistance. Curr. Opin. Microbiol. 3:2000;496-501.
49. Fleischmann R.D., Adams M.D., White O., Clayton R.A., Kirkness E.F., Kerlavage A.R., Bult C.J., Tomb J.F., Dougherty B.A., Merrick J.M.et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 269:1995;496-512.
50. Loferer H. Mining bacterial genomes for antimicrobial targets. Mol. Med. Today. 6:2000;470-474.
51. Eisen M.B., Brown P.O. DNA arrays for analysis of gene expression. Methods Enzymol. 303:1999;179-205.
52. DeRisi J.L., Iyer V.R., Brown P.O. Exploring the metabolic and genetic control of gene expression on a genomic scale. Science. 278:1997;680-686.
53. Chee M., Yang R., Hubbell E., Berno A., Huang X.C., Stern D., Winkler J., Lockhart D.J., Morris M.S., Fodor S.P. Accessing genetic information with high-density DNA arrays. Science. 274:1996;610-614.
54. Harrington C.A., Rosenow C., Retief J. Monitoring gene expression using DNA microarrays. Curr. Opin. Microbiol. 3:2000;285-291.
55. Pandey A., Mann M. Proteomics to study genes and genomes. Nature. 405:2000;837-846.
56. Washburn M.P., Yates J.R. Analysis of the microbial proteome. Curr. Opin. Microbiol. 3:2000;292-297.